Shire to present Vyvanse, Intuniv studies at psychiatrist meetings
PHILADELPHIA British drug maker Shire will present data on two attention deficit hyperactivity disorder treatments in New Orleans starting this week, Shire said.
The company said it would present data on Vyvanse (lisdexamfetamine dimesylate) capsules and Intuniv (guanfacine) extended-release tablets at two psychiatrist meetings between Thursday and Wednesday.
“We believe that the Vyvanse and Intuniv study findings will be an important contribution to the current collection of ADHD research,” Shire Pharmaceuticals SVP research and development Jeffrey Jonas said. “These studies reflect Shire’s commitment to advancing ADHD treatment research.”